Zoon Kathryn C 4
4 · Emergent BioSolutions Inc. · Filed May 4, 2026
Research Summary
AI-generated summary of this filing
Emergent BioSolutions Director Kathryn Zoon Sells Shares, Receives RSUs
What Happened
Kathryn C. Zoon, a member of Emergent BioSolutions' board of directors, sold 17,202 shares in open-market transactions on May 1, 2026 for total proceeds of $144,453, and on April 30, 2026 received equity awards: 25,344 restricted stock units (RSUs) and 11,296 stock options (both reported as acquired at $0.00). The share sales were executed under a Rule 10b5-1 trading plan to cover tax obligations related to RSU vesting.
Key Details
- Sale date(s): May 1, 2026.
- 16,145 shares sold at a weighted-average price of $8.36 (range $7.77–$8.70) for $134,972. (F3)
- 1,057 shares sold at a weighted-average price of $8.97 (range $8.79–$8.99) for $9,481. (F4)
- Awards (reported April 30, 2026): 25,344 RSUs (F1) and 11,296 stock options (derivative award; F5/F6).
- Reason for sale: Shares sold pursuant to a Rule 10b5-1 plan dated May 16, 2025 to satisfy tax obligations from RSU vesting on April 29, 2026. (F2)
- Vesting/terms: RSUs vest on the day prior to the one-year anniversary of the grant (Annual Grant Vesting Date), subject to continued board service. Options vest on the same Annual Grant Vesting Date; option count was determined per the plan formula using a Black‑Scholes valuation (F1, F5, F6).
- Shares owned after transaction: not specified in this filing.
Context
These transactions combine routine board compensation (annual RSU and option grants) and a pre-existing 10b5-1 sale plan used to meet tax withholding from RSU vesting. Sales under an established 10b5-1 plan are generally considered routine and do not necessarily indicate a change in the insider’s view of the company.
Insider Transaction Report
Form 4
Zoon Kathryn C
Director
Transactions
- Award
Common Stock
[F1]2026-04-30+25,344→ 97,143 total - Sale
Common Stock
[F2][F3]2026-05-01$8.36/sh−16,145$134,972→ 80,998 total - Sale
Common Stock
[F2][F4]2026-05-01$8.97/sh−1,057$9,481→ 79,941 total - Award
Stock Option (Right to Buy)
[F5][F6]2026-04-30+11,296→ 11,296 totalExercise: $7.99Exp: 2033-04-30→ Common Stock (11,296 underlying)
Footnotes (6)
- [F1]Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
- [F2]Represents the number of shares sold by the Reporting Person. Shares were sold pursuant to a Rule 10b5-1 trading plan, dated May 16, 2025, for the purpose of satisfying tax obligations relating to the vesting of RSUs on April 29, 2026.
- [F3]The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $7.77 to $8.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F4]The price reported in Column 4 is a weighted average price for sales executed on the same day within a one-dollar price range. These shares were sold in multiple transactions at prices ranging from $8.79 to $8.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F5]Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
- [F6]The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
Signature
/s/ Richard S. Lindahl, Attorney-in-fact|2026-05-04